EMEA (Europe, Middle East and Africa) Resistant Pseudomonas Aeruginosa Infections Drugs Market Report 2017

December 2017 | 101 pages | ID: E2EFF32C7F4EN
QYResearch

Abstracts

In this report, the EMEA Resistant Pseudomonas Aeruginosa Infections Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Resistant Pseudomonas Aeruginosa Infections Drugs for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Resistant Pseudomonas Aeruginosa Infections Drugs market competition by top manufacturers/players, with Resistant Pseudomonas Aeruginosa Infections Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including

• ContraFect Corp
• Inhibrx LP
• Achaogen Inc
• LegoChem Biosciences Inc
• Melinta Therapeutics Inc
• Novartis AG
• AmpliPhi Biosciences Corp
• Biolytics Pharma
• Shionogi & Co Ltd

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• Semi-Synthetic Penicillin
• Cephalosporin
• Lactam Drugs
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospital
• Clinic
• Home Care

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Resistant Pseudomonas Aeruginosa Infections Drugs Market Report 2017

1 RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS OVERVIEW

1.1 Product Overview and Scope of Resistant Pseudomonas Aeruginosa Infections Drugs
1.2 Classification of Resistant Pseudomonas Aeruginosa Infections Drugs
  1.2.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Semi-Synthetic Penicillin
  1.2.4 Cephalosporin
  1.2.5 Lactam Drugs
  1.2.6 Others
1.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market by Application/End Users
  1.3.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Home Care
1.4 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market by Region
  1.4.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Resistant Pseudomonas Aeruginosa Infections Drugs (2012-2022)
  1.5.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2022)

2 EMEA RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Competition by Players/Manufacturers
  2.1.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price by Players (2012-2017)
2.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs (Volume and Value) by Type/Product Category
  2.2.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price by Type (2012-2017)
2.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs (Volume) by Application
2.4 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs (Volume and Value) by Region
  2.4.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Region (2012-2017)

3 EUROPE RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
  3.1.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
3.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Type
3.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Application
3.4 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Countries (2012-2017)
  3.4.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries (2012-2017)
  3.4.3 Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
  3.4.4 France Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
  3.4.5 UK Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
  3.4.6 Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
  3.4.7 Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)

4 MIDDLE EAST RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
  4.1.1 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
4.2 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Type
4.3 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Application
4.4 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
  4.4.4 Israel Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
  4.4.5 UAE Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
  4.4.6 Iran Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)

5 AFRICA RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
  5.1.1 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
5.2 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Type
5.3 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Application
5.4 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Countries (2012-2017)
  5.4.2 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries (2012-2017)
  5.4.3 South Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)

6 EMEA RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 ContraFect Corp
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Inhibrx LP
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Achaogen Inc
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 LegoChem Biosciences Inc
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Melinta Therapeutics Inc
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Novartis AG
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 AmpliPhi Biosciences Corp
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Biolytics Pharma
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Shionogi & Co Ltd
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview

7 RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MANUFACTURING COST ANALYSIS

7.1 Resistant Pseudomonas Aeruginosa Infections Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Resistant Pseudomonas Aeruginosa Infections Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Resistant Pseudomonas Aeruginosa Infections Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET FORECAST (2017-2022)

11.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Price and Trend Forecast (2017-2022)
11.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Type (2017-2022)
11.7 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Resistant Pseudomonas Aeruginosa Infections Drugs
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume (K Pcs) by Type (2012-2022)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Semi-Synthetic Penicillin Product Picture
Figure Cephalosporin Product Picture
Figure Lactam Drugs Product Picture
Figure Others Product Picture
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume (K Pcs) by Application (2012-2022)
Figure EMEA Sales Market Share of Resistant Pseudomonas Aeruginosa Infections Drugs by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Home Care Examples
Table Key Downstream Customer in Home Care
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Million USD) by Region (2012-2022)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2022)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume (K Pcs) of Major Players (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Players (2012-2017)
Figure 2016 Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Players
Figure 2017 Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Players
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) by Players (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Players (2012-2017)
Table 2016 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Players
Table 2017 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Players
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price (USD/Pcs) by Players (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Market Share by Type (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Resistant Pseudomonas Aeruginosa Infections Drugs by Type (2012-2017)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Resistant Pseudomonas Aeruginosa Infections Drugs by Type in 2016
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price (USD/Pcs) by Type (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Market Share by Application (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Resistant Pseudomonas Aeruginosa Infections Drugs by Application (2012-2017)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application in 2016
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Market Share by Region (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Region (2012-2017)
Figure Sales Market Share of Resistant Pseudomonas Aeruginosa Infections Drugs by Region (2012-2017)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share in 2016
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Resistant Pseudomonas Aeruginosa Infections Drugs by Region (2012-2017)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share Regions in 2016
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price (USD/Pcs) by Region (2012-2017)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
Table Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Type (2012-2017)
Table Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Type (2012-2017)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Type in 2016
Table Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Application (2012-2017)
Table Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Application (2012-2017)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Application in 2016
Table Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Countries (2012-2017)
Table Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries in 2016
Table Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) by Countries (2012-2017)
Table Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries in 2016
Figure Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure France Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure UK Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Benelux Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Type (2012-2017)
Table Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Type (2012-2017)
Figure Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Type (2012-2017)
Table Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Applications (2012-2017)
Table Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Applications (2012-2017)
Figure Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application in 2016
Table Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume (K Pcs) by Countries (2012-2017)
Table Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Market Share by Countries in 2016
Table Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) by Countries (2012-2017)
Table Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries in 2016
Figure Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Israel Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure UAE Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Iran Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Type (2012-2017)
Table Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2012-2017)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2012-2017)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type in 2016
Table Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Application (2012-2017)
Table Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2012-2017)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2012-2017)
Table Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume (K Pcs) by Countries (2012-2017)
Table Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries in 2016
Table Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) by Countries (2012-2017)
Table Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries in 2016
Figure South Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Nigeria Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Algeria Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Table ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Basic Information List
Table ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share in EMEA (2012-2017)
Figure ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share in EMEA (2012-2017)
Table Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Basic Information List
Table Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share in EMEA (2012-2017)
Figure Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share in EMEA (2012-2017)
Table Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Basic Information List
Table Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share in EMEA (2012-2017)
Figure Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share in EMEA (2012-2017)
Table LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Basic Information List
Table LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share in EMEA (2012-2017)
Figure LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share in EMEA (2012-2017)
Table Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Basic Information List
Table Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share in EMEA (2012-2017)
Figure Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share in EMEA (2012-2017)
Table Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Basic Information List
Table Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share in EMEA (2012-2017)
Figure Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share in EMEA (2012-2017)
Table AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Basic Information List
Table AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share in EMEA (2012-2017)
Figure AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share in EMEA (2012-2017)
Table Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Basic Information List
Table Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share in EMEA (2012-2017)
Figure Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share in EMEA (2012-2017)
Table Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Basic Information List
Table Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share in EMEA (2012-2017)
Figure Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share in EMEA (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Resistant Pseudomonas Aeruginosa Infections Drugs
Figure Manufacturing Process Analysis of Resistant Pseudomonas Aeruginosa Infections Drugs
Figure Resistant Pseudomonas Aeruginosa Infections Drugs Industrial Chain Analysis
Table Raw Materials Sources of Resistant Pseudomonas Aeruginosa Infections Drugs Major Manufacturers in 2016
Table Major Buyers of Resistant Pseudomonas Aeruginosa Infections Drugs
Table Distributors/Traders List
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) and Growth Rate Forecast (2017-2022)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Price (USD/Pcs) and Trend Forecast (2017-2022)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) Forecast by Region (2017-2022)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share Forecast by Region (2017-2022)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share Forecast by Region (2017-2022)
Table Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) Forecast by Type (2017-2022)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share Forecast by Type (2017-2022)
Table EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) Forecast by Application (2017-2022)
Figure EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources